New drug combination offers ovarian cancer breakthrough

Thousands of women with ovarian cancer could benefit from a revolutionary drug combination after it was shown to significantly shrink tumours in almost half of patients with the disease.

The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.

One patient who benefited told how doctors had warned her there was nothing they could do after her ovarian cancer resisted both chemotherapy and hormone therapy.

But the breakthrough treatment has now helped her beat the disease for a second time. Her tumours have been obliterated, while the latest scan results show no evidence of disease.

The phase 2 trial, led by the Royal Marsden NHS foundation trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.

Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.

All the patients had low-grade serous ovarian cancer, which tends to affect younger women.

Dr Susana Banerjee, the global lead investigator of the study presented at the American Society of Clinical Oncology’s annual meeting in Chicago, said it could represent a “significant breakthrough”.

“These initial results could be fantastic news for women with low-grade serous ovarian cancer, indicating a far more effective option than current treatments,” she said.

Avutometinib is a dual RAF and MEK inhibitor, a type of targeted drug that blocks certain proteins that help control cancer growth and survival. Studies have shown the drug can become ineffective over time as tumours develop resistance to treatment.

However, when combined with defactinib – which combats a protein that encourages drug resistance – avutometinib works more efficiently.

Study co- author Dr Kathleen Moore, of the Stephenson Cancer Centre in Oklahoma, said the results of the new treatment were “very exciting”. “The beauty of the combination is that you’re outsmarting two ways that these tumours become resistant,” she said. While survival data is not yet available from the new study, previous studies indicate patients live an average of 23 months following treatment with this drug combination before their cancer progresses.

“Low-grade serous ovarian cancer does not respond well to currently approved treatments, so these results could represent a significant breakthrough,” said Banerjee. She said she was “hopeful” the results would lead to the drug combination becoming “a standard of care for women”.